Search Results - "Morais, José Augusto Guimarães"

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    A Two-Way Proposal for the Determination of Bioequivalence for Narrow Therapeutic Index Drugs in the European Union by Paixao, Paulo, Garcia Arieta, Alfredo, Silva, Nuno, Petric, Zvonimir, Bonelli, Milton, Morais, José Augusto Guimarães, Blake, Kevin, Gouveia, Luís Filipe

    Published in Pharmaceutics (01-05-2024)
    “…In the European Union, bioequivalence (BE) for narrow therapeutic index (NTI) drugs is currently demonstrated when the 90% confidence interval for the ratio of…”
    Get full text
    Journal Article
  2. 2

    Evaluation of a Proposed Approach for the Determination of the Bioequivalence Acceptance Range for Narrow Therapeutic Index Drugs in the European Union by Paixão, Paulo, Silva, Nuno, Guerreiro, Rita Bento, Blake, Kevin, Bonelli, Milton, Morais, José Augusto Guimarães, García-Arieta, Alfredo, Gouveia, Luís Filipe

    Published in Pharmaceutics (31-10-2022)
    “…Bioequivalence (BE) of products containing narrow therapeutic index (NTI) drugs in the European Union is currently established by demonstrating that the 90%…”
    Get full text
    Journal Article
  3. 3

    The New European Medicines Agency Guideline on the Investigation of Bioequivalence by Morais, José Augusto Guimarães, Lobato, Maria do Rosário

    Published in Basic & clinical pharmacology & toxicology (01-03-2010)
    “…:  In this MiniReview, the main modifications made during the revision of the current Note for Guidance on the Investigation of Bioavailability and…”
    Get full text
    Journal Article Conference Proceeding
  4. 4

    A Proposed Approach for the Determination of the Bioequivalence Acceptance Range for Narrow Therapeutic Index Drugs in the European Union by Paixão, Paulo, Guerreiro, Rita Bento, Silva, Nuno, Blake, Kevin, Bonelli, Milton, Morais, Jose Augusto Guimarães, Garcia Arieta, Alfredo, Gouveia, Luis Filipe

    Published in Clinical pharmacology and therapeutics (01-02-2022)
    “…The current regulatory criterion for bioequivalence of narrow therapeutic index (NTI) drugs in the European Union requires that the 90% confidence interval for…”
    Get full text
    Journal Article